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Abstract
Nuclear activated β-catenin plays a causative role in colorectal cancers (CRC) but remains an elusive therapeutic target.
Using human CRC cells harboring different Wnt/β-catenin pathway mutations in APC/KRAS or β-catenin/KRAS genes, and
both genetic and pharmacological knockdown approaches, we show that oncogenic β-catenin signaling negatively regulates
the expression of NHERF1 (Na+/H+ exchanger 3 regulating factor 1), a PDZ-adaptor protein that is usually lost or
downregulated in early dysplastic adenomas to exacerbate nuclear β-catenin activity. Chromatin immunoprecipitation (ChIP)
assays demonstrated that β-catenin represses NHERF1 via TCF4 directly, while the association between TCF1 and the
Nherf1 promoter increased upon β-catenin knockdown. To note, the occurrence of a cytostatic survival response in settings
of single β-catenin-depleted CRC cells was abrogated by combining NHERF1 inhibition via small hairpin RNA (shRNA) or
RS5517, a novel PDZ1-domain ligand of NHERF1 that prevented its ectopic nuclear entry. Mechanistically, dual NHERF1/
β-catenin targeting promoted an autophagy-to-apoptosis switch consistent with the activation of Caspase-3, the cleavage of
PARP and reduced levels of phospho-ERK1/2, Beclin-1, and Rab7 autophagic proteins compared with β-catenin knockdown
alone. Collectively, our data unveil novel β-catenin/TCF-dependent mechanisms of CRC carcinogenesis, also offering
preclinical proof of concept for combining β-catenin and NHERF1 pharmacological inhibitors as a mechanism-based
strategy to augment apoptotic death of CRC cells refractory to current Wnt/β-catenin-targeted therapeutics.
Introduction
Nuclear activated β-catenin caused by Wnt-pathway muta-
tions is the earliest driving event in hereditary (10%) and
sporadic (90%) human colorectal cancers (CRC) [1].
Deletion of the tumor suppressor adenomatous polyposis
coli (APC) (>80%) or ‘gain-of-function’ mutations in
GSK3β-target residues in β-catenin gene (5–10%) increase
* Addolorata Maria Luce Coluccia
malu.coluccia@unisalento.it
michele.maffia@unisalento.it
1 Laboratory of Clinical Proteomics, Giovanni Paolo II Oncology
Hospital, I-73100 Lecce, Italy
2 Functional Biomorphology Laboratory, IRCCS Istituto Tumori
“Giovanni Paolo II”, Bari, Italy
3 Department of Biological and Environmental Sciences and
Technologies, University of Salento, I-73100 Lecce, Italy
4 Department of Drug Chemistry and Technologies, Sapienza
University of Rome, Laboratory affiliated to Istituto Pasteur Italia
– Fondazione Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185
Roma, Italy
5 Department of Clinical Medicine, San Gerardo Hospital,
University of Milano-Bicocca, I-20052 Monza, Italy
6 Department of Biochemistry, Sapienza University of Rome,
Laboratory affiliated to Istituto Pasteur Italia – Fondazione Cenci
Bolognetti, Piazzale Aldo Moro 5, I-00185 Roma, Italy
7 U1192-Laboratoire Protéomique, Réponse Inflammatoire et
Spectrométrie de Masse (PRISM), F-59000 Lille, France
Electronic supplementary material The online version of this article
(https://doi.org/10.1038/s41388-018-0170-y) contains supplementary
material, which is available to authorized users.
12
34
56
78
90
()
;,:
the nuclear import of β-catenin with ensuing aberrant acti-
vation of TCF/LEF (T-cell factor/lymphoid enhanced fac-
tor) transcriptional factors. Activating mutations of KRAS
and BRAF genes are detected in up to 60% of CRC, not
long after APC or β-catenin mutations, and contribute to
enforce the oncogenic signaling of β-catenin also conveying
an invasive and metastatic behavior in cancer cells [2].
Despite its causative role in CRC, however, β-catenin
remains an elusive therapeutic target. Targeting of β-catenin
by small hairpin RNAs (shRNAs) or pharmacological
inhibitors reduces the growth of established CRC xeno-
grafts in vivo without affecting the viability of malignant
cells [3, 4]. CRC cells harboring inducible β-catenin
shRNAs undergo cell cycle arrest, differentiate into polar-
ized epithelial cells but rapidly resume their proliferative
Fig. 1 β-catenin represses NHERF1 expression through associating
with TCF4. a Ls174T and DLD1 cells stably transfected with a dox-
ycycline (Dox)-inducible small hairpin (sh)RNA for β-catenin (shβ-
Cat) or a scramble shRNA (shCtr) as control were cultured without (−)
or with (+) Dox for 5 days. Total cell lysates were then probed for β-
catenin (β-Cat) and NHERF1 protein amounts. Tubulin served as a
loading control. b Ls174Tshβ-Cat and DLD1shβ-Cat cells expressing
a Dox-inducible shRNA for β-catenin were cultured without (−) or
with (+) Dox for 1, 2, 3, or 5 days and then assessed by western
blotting as indicated. c An equal amount of RNA (1 μg) of Ls174Tshβ-
Cat and DLD1shβ-Cat cells cultured in the absence (−) or presence of
Dox at the indicated time points, was analyzed by RT-PCR for
assessing nherf1 and β-actin mRNA levels. The normalized nher-
f1expression versus β-actin mRNA at day 5 was quantified by using
Image J analysis software for Windows. Data from three independent
experiments were presented as means ± SEM (*p < 0.05). d ChIP of
TCF1 and TCF4 in the Nherf1 promoter region in Ls174Tshβ-Cat and
DLD1shβ-Cat cells cultured in the absence (−) or presence of Dox (+)
for 5 days. qPCR was performed to quantify ChIP assay results.
Enrichment was quantified relative to input controls. An anti-IgG
antibody was used as a negative control. Results are represented as the
average ± SD of three independent experiments (*p < 0.01)
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potential when relieved from β-catenin inhibition in vitro [5,
6]. Thus, from a biological and therapeutic perspective, a
better characterization of the signaling outcome of β-catenin
knockdown could provide new molecular events tied
to survival control in CRC tumorigenesis that could
be potentially used in combination therapy to improve
the efficacy of Wnt-targeted approaches at early disease
stages.
NHERF1 (Na+/H+ exchanger 3 regulating factor 1) is a
membrane adaptor protein that contains two tandem PDZ
(post-synaptic density 95/discs large/zona occludens 1)
domains and physiologically recruits β-catenin underneath
the plasma membrane to shape proper tissue morphogenesis
and homeostasis [7]. Recent data earmark NHERF1 as a
tumor suppressor upstream of Wnt/β-catenin-driven intest-
inal tumorigenesis in vivo [8]. The complete lack of
NHERF1 expression, either by shRNA knockdown in CRC
cells or by gene knockout (NHERF1−/−) in ApcMin/+ mutant
mice that develop multiple intestinal adenomas, was
reported to increase tumor growth and the transactivating
effects of β-catenin [8]. These data have relatively explained
the heterogeneous pattern of NHERF1 observed in primary
CRC [9–11], where membranous expression of NHERF1 is
usually lost in dysplastic adenomas, and either absent or
low/ectopically re-expressed thorough the cytoplasm and
nuclei in approximately half of differentiated adenocarci-
nomas [12, 13].
Little is known about molecular mechanisms governing
the early loss-of-NHERF1 expression in CRC and, in par-
ticular, the impact of oncogenic β-catenin remains
unexploited. Using CRC cells harboring different Wnt/β-
catenin pathway mutations and low-NHERF1-levels at
baseline, we show that genetic or pharmacological knock-
down of β-catenin is sufficient to increase NHERF1 as
a major driver of a cytoprotective autophagic response.
This prompted us to investigate a double β-catenin/
NHERF1-inhibitory strategy as a fruitful approach to aug-
ment apoptotic death of CRC cells refractory to Wnt-
targeted agents, indicating RS5517 as a novel NHERF1/
PDZ1-domain ligand antagonist with a promising ther-
apeutic value.
Results
β-catenin represses NHERF1 expression by
associating with TCF4
Mechanisms underlying the early lack of NHERF1 in CRC
tumorigenesis remain unclear [7]. To determine the impact
Fig. 2 Ectopic cytoplasmic and nuclear overexpression of NHERF1 in
β-catenin-depleted CRC adenocarcinoma cells. a Ls174Tshβ-Cat were
cultured in the absence or presence of Dox (−Dox/+Dox) for 5 days,
stained with primary antibodies for β-catenin (β-Cat) or NHERF1 and
visualized with a fluorescent IgG-TRITC (for β-Cat) or IgG-FITC (for
NHERF1) secondary antibodies by laser scanning confocal micro-
scopy. DNA was stained with 4′,6-diamidino-2-phenylindole (DAPI).
A merge of the two fluorescence signals and DAPI staining is also
shown (Magnification, ×60). Each confocal image is representative of
three independent experiments. b DLD1shβ-Cat cells were cultured in
the absence or presence of 2 μg/mL of Dox (−Dox/+Dox) for 5 days
and then fractionated to obtain purified extracts from either membrane,
cytosol, and nucleus of cells, as described in Methods section. Equal
amounts of each cell extract (100 μg) were separated by SDS-PAGE
and probed with the indicated antibodies
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of β-catenin on NHERF1 expression, we used an integrated
doxycycline (Dox)-inducible shRNA vector to silence β-
catenin in two human cell lines that recapitulate the earliest
events implicated in CRC (Ls174T have mutated β-catenin/
KRAS genes and DLD-1 have mutated APC/KRAS genes)
[14–16].
β-catenin was successfully silenced in shβ-catenin stably
transfected Ls174T and DLD-1 cells (below named
Ls174Tshβ-Cat and DLD1shβ-Cat) cultured with Dox
(+Dox) compared with untreated cells (−Dox) or a mock
clone expressing a negative control shRNA (shCtr) (Fig. 1a,
b). Both CRC cell lines expressed low-steady-state levels of
NHERF1 (Fig. 1b, c), while its mRNA transcript and pro-
tein levels was gradually increased in shβ-Cat-depleted
CRC cells maintained under Dox (+Dox), achieving a peak
of induction upon complete β-catenin knockdown (Fig. 1b,
c). Then we performed ChIP assays to determine whether β-
catenin regulates NHERF1 via recruiting key transcriptional
mediators of the Wnt pathway like TCF1, also called tran-
scription factor 7 (TCF7), and TCF4 also called transcrip-
tion factor 7-like 2 (TCF7L2), both of which involved in
CRC carcinogenesis [1, 2]. We observed that knockdown of
β-catenin strikingly reduced the binding of TCF4 with the
Nherf1 promoter, while promoting the association with
TCF1 in both CRC cell lines (Fig. 1d).
We also examined the intracellular distribution of
NHERF1 and β-catenin in Ls174Tshβ-Cat cells by laser
scanning confocal microscopy (Fig. 2a). β-catenin was
nearly undetectable in Dox-treated cells correlating with a
more pronounced ectopic staining of NHERF1 compared
with the Dox-untreated control samples (Fig. 2a). Similar
results were obtained by testing DLD1shβ-Cat cells (data
not shown), which were also subjected to cell fractionation
experiments to assess changes on NHERF1 subcellular
compartmentalization during β-catenin knockdown (Fig.
2b). A fraction of cortical β-catenin was evident in Dox-
untreated CRC cells (−Dox), although it was predominantly
accumulated in the cytosolic and nuclear fractions, in line
with an oncogenic β-catenin/TCF-transcriptional activation.
Following Dox-exposure (+Dox), β-catenin remained evi-
dent only in the nuclear extracts with ensuing increased
cytoplasmic/nuclear NHERF1 levels vs Dox-untreated
(−Dox) cells.
We also observed that NHERF1 was significantly upre-
gulated in Ls174Tshβ-Cat cells treated with FH535 and
pyrvinium pamoate, two unrelated drugs that have been
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Fig. 3 Small molecule inhibitors of β-catenin promote NHERF1
overexpression and mislocalization in CRC cells. a Subconfluent
Ls174Tshβ-Cat were co-transfected with the luciferase reporter con-
structs TOPflash or FOPflash as reported in Methods section. At 24 h
after transfection, cells were treated with vehicle alone (DMSO),
FH535 (1 μM) or pyrvinium pamoate (150 nM) for additional 72 h.
Luciferase activity was expressed as fold activation compared with
carrier control cells. Values represent means ± SD of three repre-
sentative experiments. b After 4 days of treatment with DMSO, FH535
(1 μM) or pyrvinium pamoate (150 nM), total cell lysates were probed
for β-catenin (β-Cat), c-Myc and NHERF1 expression. Tubulin served
as a loading control. c Ls174Tshβ-Cat cells exposed for 4 days to
DMSO, FH535 (1 μM) or pyrvinium pamoate (150 nM) were analyzed
by propidium iodide-staining and flow cytometric analysis for assay-
ing cell cycle distribution, as described in Methods section. A repre-
sentative dot plot of three replicate experiments shows the percentages
of cells into different phases of the cell cycle for each indicated
treatment. d Each confocal image is representative of three indipendent
immunofluorescence analyses of NHERF1 by a rabbit polyclonal
antibody visualized with a fluorescent IgG-FITC secondary antibody
for the indicated treatments (left panels). DAPI staining (right panels)
is also shown (Magnification, ×60)
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Fig. 4 β-catenin-silenced CRC cells show a unique protein profile
centred around autophagy and energy metabolism. Ls174T and
DLD1 cells expressing a doxycycline (Dox)-inducible shRNA for β-
catenin (Ls174Tshβ-Cat and DLD1shβ-Cat) were cultured without or
with 2 μg/mL of Dox (−Dox/+Dox) for 1, 3, or 5 days. a A repre-
sentative image of cells from one of the six fields captured from each
well by using a camera attached to an inverted Olympus IX51
microscope is shown. b After 5 days of treatment without or with
doxycycline (−Dox/+Dox), Ls174Tshβ-Cat cells were analyzed by
propidium iodide-staining and flow cytometric analysis for assaying
cell cycle distribution, as described in Methods section. A repre-
sentative dot plot of three replicate experiments shows the percentages
of cells into different phases of the cell cycle for each indicated
treatment (left panels). Under the same experimental conditions,
Ls174Tshβ-Cat cells were analyzed for the presence of MDC-positive
autophagosomes, distinct dot-like structures trapped in acidic,
membrane-rich organelles distributed in the cytoplasm or localizing in
the perinuclear regions of CRC cells (Magnification, ×60). The num-
bers indicate the percentage of autophagy induction for each treatment
condition. c After 5 days of treatment without or with doxycycline
(−Dox/+Dox), cell cycle distribution of DLD1shβ-Cat cells was
analyzed by propidium iodide-staining and flow cytometric analysis. A
representative plot of three replicate experiments shows the percen-
tages of cells into different phases of the cell cycle for each indicated
treatment (left panels). DLD1shβ-Cat cells were analyzed for the
presence of MDC-positive autophagosomes, as previously reported for
Ls174Tshβ-Cat cells (Magnification, ×60). The numbers indicate the
percentage of autophagy induction for each treatment condition. d
Total cell lysates from Ls174Tshβ-Cat and DLD1shβ-Cat cultured
without (−) or with (+) Dox for 5 days were assessed by western
blotting with the indicated antibodies
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reported to block β-catenin signaling via different
mechanisms (Fig. 3). FH535 is a sulfonamide-based com-
pound that suppresses β-catenin/TCF-mediated transcrip-
tion without affecting β-catenin levels [17]. Pyrvinium is an
anthelmintic drug that promotes β-catenin degradation via
activation of CK1α (casein kinase1α) [18]. Both drugs
reduced transcription from the β-catenin/TCF-responsive
reporter plasmid TOPflash (Fig. 3a) and expression of c-
Myc, a β-catenin transcriptional target that promotes cell
proliferation (Fig. 3b). The two drugs induced CRC cell
cycle arrest without significant apoptosis (Fig. 3c) [5, 6] and
increased low-endogenous NHERF1 levels, as well as its
ectopic cytoplasmic/nuclear subcellular distribution,
although at a higher extent in pyrvinium vs FH535-treated
cells (Fig. 3b, d).
To our knowledge, these data unveils a new oncogenic
role for β-catenin in CRC through very early
NHERF1 suppression at the transcriptional level via TCF4
directly.
Genetic targeting of β-catenin and NHERF1 causes
massive CRC apoptosis
Knockdown of β-catenin promoted cell differentiation
coupled to a prominent vacuolization in Dox-treated
(+Dox) Ls174Tshβ-Cat and DLD-1shβ-Cat cells vs their
untreated counterparts (−Dox) (Fig. 4a) [5, 6]. These
changes were reversible on Dox removal (data not shown).
Similarly to pharmacological targeting of β-catenin (Fig. 3),
genetic depletion of β-catenin was sufficient to cause cell
cycle arrest (Fig. 4b, c, left panels) sustaining an adaptive
autophagic response, as judged by staining for mono-
dansylcadaverine (MDC) used as a hallmark of autophagic
vacuoles (Fig. 4b, c, right panels). As shown in Fig. 4d,
heightened endogenous levels of NHERF1 in settings of
viable β-catenin-depleted CRC cells also correlated with
hyper-phosphorylated ERK1/2 (pERK1/2) and increased
levels of the cell cycle inhibitor p27, as well as of key
endocytosis/autophagy regulators, such as the microtubule-
associated protein light chain 3 (LC3), Beclin-1 (BECN1),
Cathepsin D, the regulatory V1G1 subunit of the vacuolar
ATPase (V-ATPase), the small GTPase Rab7 and its
effector RILP [19, 20]. Specifically, the accumulation of
LC3-II, Beclin-1, and Cathepsin D isoforms were specific
molecular makers of autophagy predicted based on mor-
phological parameters (Fig. 4a). These findings were cor-
roborated by an unbiased broad proteomic characterization
indicating that 1161 proteins were differentially expressed
in Ls174Tshβ-Cat cells cultured with or without doxycy-
cline (±Dox) (Supplementary Figure S1). The heat-map
generated by Perseus segregated samples into two separated
branches characterized respectively by 464 proteins upre-
gulated (Cluster 1) and 697 proteins downregulated (Cluster
2) in β-catenin-depleted cells. Each protein cluster was also
enriched with specific signaling cascades based on KEGG
(Kyoto Encyclopedia of Genes and Genomes) pathway
analysis using STRING software (Table 1). These proteins
were statistically categorized by STRING (false discovery
rate ≤1.31e−05) showing that Cluster 1 was enriched with
proteins involved in the assembling of actin cytoskeleton
and adherens junctions, fatty acid degradation, phagosome/
lysosome maturation, autophagy, and endocytosis. Con-
versely, downregulated proteins into the Cluster 2 were
involved in the regulation of spliceosome, RNA transport
and ribosome biogenesis. This proteomic profiling corro-
borated the molecular changes reported in Fig. 4d, ear-
marking differences into our dataset in terms of energy
metabolism, actin filament-based processes and especially
autophagic/endocytic processes.
Overall these considerations prompted us to investigate
whether NHERF1 could play a role in modulating ERK1/2
and Rab7 expression upon β-catenin depletion (Fig. 5). To
this end, Ls174Tshβ-Cat or DLD1shβ-Cat cells were tran-
siently transfected with NHERF1 targeted shRNAs
(shNHERF1) or scramble shRNAs as control (shCtr) and
then cultured with or without Dox (±Dox) to modulate
concomitantly stable siβ-catenin expression. As shown in
Fig. 5a, NHERF1 knockdown alone did not alter overall
phospho-ERK1/2, Beclin-1 (BECN1), Rab7, and PARP
protein levels at baseline, while combined targeting of
NHERF1 and β-catenin annulled the hyper-activation of
ERK1/2 and the accumulation of the autophagy markers
Beclin-1 (BECN1) and Rab7 elicited by single-β-catenin
depletion (Fig. 5a, 4d). Such molecular changes were con-
sistent with a massive apoptotic death occurrence in Dox-
treated Ls174Tshβ-Cat/shNHERF1 (75 ± 6%) and
DLD1shβ-Cat/shNHERF1 (82 ± 8%) cells, compared with
<5% in controls (shβ-Cat/siCtr+Dox or shβ-Cat/
shNHERF1−Dox) (Fig. 5b, c), as further confirmed by the
cleavage of PARP (Fig. 5a) and Caspase-3 activity (Fig.
5d). Interestingly, we also noticed a modest increase of β-
catenin protein amounts in shβ-Cat/shNHERF1 maintained
with or without Dox for 4 days (Fig. 5a), in keeping with
additive affects that NHERF1 knockdown extents on β-
catenin stabilization reported by others [8]. Moreover,
NHERF1 knockdown alone conferred a moderate clono-
genic advantage to Dox-untreated Ls174Tshβ-Cat or
DLD1shβ-Cat cells (Supplementary Figures S2A and S2B)
which showed a more sprouted/invasive phenotype when
cultured in sub-confluent monolayers (Fig. 5b) or in soft
agar (Supplementary Figure S2C).
Collectively, these data indicate that combining
NHERF1 inhibition in settings of β-catenin-silenced CRC
cells, in which NHERF1 is highly/ectopically re-expressed,
is mandatory to promote an autophagy-to-apoptosis switch
in CRC cells refractory to single-β-catenin targeting.
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A novel NHERF1/PDZ1-domain antagonist prevents
its nuclear import and synergizes with β-catenin
inhibitors in promoting CRC apoptosis
Previous studies focused on small molecule ligands of the
PDZ1-domain of NHERF1 to prevent its ectopic cyto-
plasmic/nuclear mislocalization and oncogenic function
[21–23]. These studies predicted the canonical inactivating
binding motif for the NHERF1 PDZ1-domain on four D/E-
(S/T)-X-(L/V/I/M) residues that are commonly contained at
the C-terminal of its specific ligands, such as DSLL for the
β2-adrenergic receptor (β2-AR) or ETWM for the para-
thyroid hormone receptor (PTHR) [24]. Based on these
premises, we herein evaluated the conformational flexibility
of NHERF1 PDZ1-DSLL and PDZ1-ETWM peptide
complexes by molecular dynamics (MD) simulations to
draw a consensus pharmacophore model, as described in
Materials and Methods [25, 26]. An in-house library of
6000 compounds was screened using the pharmacophore
model leading to the selection of RS5517 as the only one of
six lowest-energy derivatives with remarkable cytotoxicity
in vitro (Fig. 6 and data not shown).
The chemical structure of RS5517, namely 3-benzyl-5-
chloro-N-(4-(hydroxymethyl)phenyl)-1H-indole-2-carbox-
amide, is depicted in Fig. 6a. The analysis of the binding
mode of RS5517 led us to identify a series of residues
involved in the interactions at the NHERF1 PDZ1 domain
(Fig. 6b). Specifically: (i) a key Pi-cation interaction
between the R80 guanidine and the benzyl group at position
3 of the indole of RS5517; (ii) hydrophobic contacts
between the 2-(4-hydroxymethyl)benzoyl moiety and F27
and I79 of the PDZ1, and between the indole nucleus and
V76; (iii) two H-bonds with L27 backbone.
To address the inhibitory effect of RS5517, we resorted
to test the effect of this molecule on NHERF1/PDZ1
domain in vitro. A construct encoding for NHERF1 PDZ1
was expressed and challenged with a dansylated peptide
corresponding to the C-terminal sequence of β2-AR (D-
NDSLL). In order to measure binding, a fluorescent pseudo-
wild type was produced by replacing Tyr38 of PDZ1 with a
Trp. Binding was then measured by Forster Resonance
energy transfer between the fluorescent donor (Trp) and
acceptor (Dansyl). Binding experiments were performed in
the presence and in the absence of a constant concentration
of RS5517 (Fig. 6c). It is evident, that, while the PDZ1 is
capable to bind the C-terminal sequence of β2-AR with an
affinity of about 10 μM, binding is essentially abolished in
the presence of RS5517. This finding confirms that RS5517
is a specific inhibitor of NHERF1/PDZ1 domain.
To evaluate the growth inhibitory effects of RS5517,
Ls174Tshβ-Cat, or DLD1shβ-Cat cells were exposed to
escalating doses (0.1–100 μM) of the compound in the
presence or absence of Dox for 4 days and then analyzed by
MTT assays. As shown in Fig. 7a, the half maximal inhi-
bitory concentration (IC50) for RS5517 in Dox-untreated
Ls174Tshβ-Cat or DLD1shβ-Cat cells expressing low
levels of NHERF1 was 52 ± 6 μM and 65 ± 11 μM,
respectively. Conversely, the equivalent IC50 value of
RS5517 was reduced to 8 ± 2 μM in Ls174Tshβ-Cat cells
and 11 ± 5 μM in DLD1shβ-Cat cells maintained under
concomitant Dox exposure. Our mechanistic investigations
suggest that the enhanced cytotoxic effects of RS5517
Table 1 The principle KEGG pathways of the upregulated and downregulated genes
Category Pathway ID Pathway description Count in gene set False discovery rate
Upregulated KEGG_ PATHWAY 01100 Metabolic pathways 80 4.79e−17
KEGG_ PATHWAY 04810 Regulation of actin cytoskeleton 24 8.5e−09
KEGG_ PATHWAY 05132 Salmonella infection 15 3.03e−08
KEGG_ PATHWAY 04145 Phagosome 19 3.45e−08
KEGG_ PATHWAY 04721 Synaptic vesicle cycle 13 3.6e−08
KEGG_ PATHWAY 05110 Vibrio cholerae infection 12 4.97e−08
KEGG_ PATHWAY 04142 Lysosome 17 6.65e−08
KEGG_ PATHWAY 04144 Endocytosis 20 5.05e−07
KEGG_ PATHWAY 05130 Pathogenic Escherichia coli infection 11 5.54e−07
KEGG_ PATHWAY 00071 Fatty acid degradation 10 7.72e−07
KEGG_ PATHWAY 04530 Tight junction 17 7.72e−07
Downregulated KEGG_ PATHWAY 03040 Spliceosome 50 1.71e−38
KEGG_ PATHWAY 03013 RNA transport 40 1.06e−22
KEGG_ PATHWAY 03008 Ribosome biogenesis in eukaryotes 27 1.68e−19
KEGG_ PATHWAY 03010 Ribosome 34 1.68e−19
KEGG_ PATHWAY 01100 Metabolic pathways 96 1.2e−14
A high confidence (0.700) was set as the threshold to define significant differences
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against Dox-treated CRC cells can be explained by inhibi-
tion of a NHERF1-mediated survival response restricted to
cells that silence β-catenin (Fig. 5). Moreover, RS5517 used
as single agent did not substantially affect the survival,
proliferation rate and clonogenic potential of shβ-Cat
transfected CRC cells (Fig. 7b, c). On the contrary, the
combined use of 10 μM RS5517 and Dox increased the
proportion of apoptotic cells in the sub-G1 peak of the cell
cycle compared with single-Dox exposure (86.6 vs 5.4%)
(Fig. 7c), by also impairing the clonogenicity of β-catenin-
depleted cells (Fig. 7d). Interestingly, RS5517 alone did not
confer any proliferative advantage to CRC cells compared
with shRNA-based NHERF1 knockdown (Supplementary
Figure S2), while promoting the outgrowth of more cohe-
sive cell colonies in soft agar (Fig. 7d).
Confocal immunofluorescence and cell fractionation
analysis revealed that RS5517 markedly prevented the
nuclear import of NHERF1 in CRC cells cultured in the
absence or presence of Dox restoring its physiological
membranous localization (Fig. 8a, b). Moreover, RS5517
did not change NHERF1 levels whilst it had stabilizing
effects on the overall β-catenin protein content regardless of
Dox treatment (Fig. 8b, c). To further exploit this issue,
DLD1shβ-Cat cells were prior exposed to RS5517 and/or
Dox for 3 days, then labeled with [35S]-methionine and
chased with complete non-radioactive medium for addi-
tional 4 or 8 h to analyze metabolic stability of β-catenin by
pull-down assays (Supplementary Figure S3). RS5517
delayed the protein degradation rate of β-catenin, as judged
by densitometric analysis (expressing the intensity of the
labeled β-catenin bands as a percentage of the value at time
0) indicating that the estimated half-life of β-catenin was
longer than 8 h in RS5517-treated samples over DMSO
control samples (−). The occurrence of apoptotic cell death
in Ls174shβ-Cat cells exposed to Dox and RS5517 (Fig. 7)
was further confirmed by the cleavage of PARP and
reduced phospho-ERK1/2, Beclin-1 (BECN1) and the Rab-
effector RILP protein levels compared to cells exposed to
single-Dox treatment (i.e., only β-catenin silenced). Intri-
guingly, the RS5517-mediated targeting of NHERF1 did
not affect the overall Rab7 expression neither at baseline or
during β-catenin knockdown (Dox setting), in contrast to
what herein reported for shRNA-mediated NHERF1
knockdown (Figs. 8c and 5a).
Fig. 5 Combined shRNA-mediated downregulation of β-catenin and
NHERF1-induces apoptosis in human CRC cells. Subconfluent
Ls174T cells stably harboring a doxycycline (Dox)-inducible shRNA
for β-catenin (Ls174Tshβ-Cat) were further transiently transfected
with 200 nM of NHERF1 targeted shRNAs (shNHERF1) or scramble
shRNAs as control (shCTR). a Total protein extracts from double shβ-
Cat/shCTR or shβ-Cat/shNHERF1 expressing cells cultured without
(−) or with (+) Dox for 5 days to simultaneously induce shRNAs for
β-catenin were assessed by western blotting with the indicated anti-
bodies. b A representative image of Dox-treated (+Dox) or untreated
shCTR or shNHERF1 expressing Ls174Tshβ-Cat or DLD1shβ-Cat
cells from one of the six fields captured from each well by using a
camera attached to an inverted Olympus IX51 microscope is shown. c
Ls174Tshβ-Cat or DLD1shβ-Cat cells expressing a scramble control
shCTR or specific shRNAs for NHERF1 (shNHERF1) were cultured
without (−) or with (+) Dox for 5 days and then labeled by Annexin
V/PI (propidium iodide) staining for apoptosis evaluation by flow
cytometry. Values represent the mean ± SD of three independent
experiments. d Caspase-3 activity was also measured and data reported
as fold induction over vehicle-treated control samples
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We finally tried to recapitulate our previous findings by
the use of RS5517 and small-molecule inhibitors of β-
catenin (Fig. 9). We show here that RS5517 synergized with
β-catenin inhibitors FH535 and pyrvinium pamoate in
triggering massive apoptosis of Ls174T and DLD1 colon
cancer cells (Fig. 9a, b), thereby preventing persistent
ERK1/2 phospho-activation mediated by single-β-catenin
targeting (Fig. 9c).
Discussion
The PDZ-scaffold protein NHERF1 is over-expressed in
breast and colon carcinomas [12–14], associated sig-
nificantly with aggressive histological grade and poor
prognosis [27–31]. By physically tethering several cancer-
related proteins, such as β-catenin [8], the tyrosine-kinase
receptors PDGFR (platelet-derived growth factor receptor)
[32] and EGFR (epidermal growth factor receptor) [33],
some Wnt-ligand engaged receptors of the Frizzled (FZD)
family [34], the tumor suppressor phosphatases PTEN
(phosphatase and tensin homolog) [35] or PHLPP (PH
leucine-rich repeat protein phosphatase) [36], NHERF1
engages in various functional complexes promoting specific
phenotypic outcomes in cancer progression and metastatic
organotropism [13, 27, 31]. However, NHERF1 is early lost
and weakly re-expressed during the adenoma-to-
adenocarcinoma transition [8, 12, 27, 35], thus playing
potential antinomic roles as tumor suppressor, when it
maintains a proper membrane localization, or tumor pro-
moter when its expression is lost or mislocalized in the
cytoplasm and nucleus [7, 9].
Loss of heterozygosity at the NHERF1 gene locus
(17q25.1) or somatic intragenic missense mutations occur in
the majority of human ovarian and breast cancers but not
other diseases examined to date [37]. The promoter of
NHERF1 gene contains estrogen-responsive elements [38],
and NHERF1 expression was correlated with increasing ER
(estrogen receptor) levels in >90% of ER-positive breast
carcinomas, while it is absent in ER-negative tumors asso-
ciated with early recurrence and poor survival [39].
Regarding CRC, a recent study stated the tumor sup-
pressor activity of NHERF1 [7, 8]. NHERF1 depletion
exacerbated the transformed phenotype in vitro and in vivo,
thereby increasing nuclear β-catenin signaling [8]. The
present study extends these findings showing that mRNA
transcript and protein levels of NHERF1 expression are
negatively regulated by oncogenic β-catenin signaling in
CRC cell lines harboring different Wnt/β-catenin pathway
mutations. Intriguingly, ChIP assays demonstrated that
nuclear activated β-catenin can regulate NHERF1 via TCF4
directly, while the interaction between TCF1 and the nherf1
promoter increases upon β-catenin knockdown. These
Fig. 6 RS5517 is a new PDZ1-domain antagonist of NHERF1. a The
chemical structure of RS5517 derivative. b Proposed binding mode for
derivative RS5517 (purple) to the NHERF1 PDZ1 domain that is
depicted as green cartoon. Residues involved in interactions were
reported as pink stick. H-bonds were shown as yellow dot lines. c
Binding of PDZ1 NHERF1 Y38W to the ligand Dansyl-NDSLL in the
presence (filled circles) and in the absence (open circles) of 5 mM
RS5517. Fluorescence data were recorded in the presence of 50 mM
Na phosphate, pH 7.2, 300 mM NaCl, 5 mM DTT, 20% DMSO, at
25 °C. Lines are the best fir to a hyperbolic binding transition. It is
evident that binding between PDZ1 NHERF1 Y38W to the ligand
Dansyl-NDSLL is abolished in the presence of RS5517
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findings provide novel insight into the β-catenin/TCF-
dependent mechanisms of CRC carcinogenesis, suggesting
that the relative amounts of β-catenin and those of different
TCFs may ultimately dictate or relieve a default repression
of nherf1 gene, in keeping with the notion that TCFs
function as powerful transcriptional activators or repressors
[40]. NHERF1 expression is known to be negatively regu-
lated by histone deacetylases [41], and was correlated with
increasing levels of HIF1α (hypoxia-inducible factor 1α)
[27, 31] that competes with TCF4 for direct binding to β-
catenin under hypoxia [42]. Thus, it seems conceivable that
either epigenetic changes and/or microenvironment cues
may further integrate different molecular factors, within or
outside the central Wnt/β-catenin cascade, to modulate
NHERF1 expression, as well as the phenotypic hetero-
geneity observed in primary human CRC [8, 11].
To our knowledge, this is the first report disclosing
NHERF1 as a major survival driver in settings of β-catenin-
depleted CRC cells which adopt a cytostatic viable pheno-
type and a unique proteomic signature centred around
autophagy and energy metabolism processes (i.e., ribosome
biogenesis, spliceosome and RNA transport, oxidative
stress and fatty acid degradation). Accordingly, recent evi-
dence earmark NHERF1 as an autophagy regulator in breast
cancers via its influence on the ubiquitin-dependent degra-
dation of BECN1, a critical component of the autophagic
core lipid kinase complex [43]. Moreover, NHERF1 was
recently implicated in the oxidative stress response regula-
tion in liver cancer cells via the recruitment of the MAPK-
activated protein kinase 2 (MK2) that belongs to the stress-
induced p38 MAPK pathway [44].
In our hands, genetic or pharmacological targeting of
NHERF1 was sufficient to prime an ‘autophagy-to-apop-
tosis switch’ that strikingly impacted the fate of CRC cells
during β-catenin knockdown. These data were remarkably
consistent across two human CRC cell lines harboring
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Fig. 7 RS5517 synergizes with shRNA-mediated silencing of β-cate-
nin in promoting CRC cell death. a Proliferation assays of Ls174Tshβ-
Cat or DLD1shβ-Cat cells exposed to increasing concentrations of
RS5517 (range 0.1–100 μM) or vehicle alone (−) in the absence or
concomitant presence of Dox (−Dox/+Dox) for 5 days. Data were
expressed as % of growth inhibition. b Ls174Tshβ-Cat or DLD1shβ-
Cat cells were treated with 10 μM RS5517 in the absence or presence
of Dox (−Dox/+Dox) for 5 days and then labelled by Annexin V-PE
for apoptosis evaluation by flow cytometry. Values represent the mean
± SD of three independent experiments. c Ls174Tshβ-Cat or
DLD1shβ-Cat cells were treated with 10 μM RS5517 (+) or DMSO as
vehicle control (−) in the absence or concomitant presence of Dox
(−Dox/+Dox) for 5 days and then analyzed by propidium iodide-
staining and flow cytometric analysis for assaying cell cycle dis-
tribution, as described in Methods section. A representative dot plot of
three replicate experiments shows the percentages of cells into dif-
ferent phases of the cell cycle for each indicated treatment. d Number
of Ls174Tshβ-Cat or DLD1shβ-Cat colonies formed in soft agar
containing DMSO or 10 μM RS5517 after 14 days. The values are
presented as mean ± SD of three independent experiments (*P < 0.05).
A representative cell colony image was captured for the indicated
treatment condition by using a camera attached to an inverted Olym-
pus IX51 microscope
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different Wnt/β-catenin pathway mutations in APC/KRAS or
β-catenin/KRAS genes, thus excluding any clonal effects.
Mechanistically, combined targeting of NHERF1 and β-
catenin triggered the activation of Caspase-3 and the clea-
vage of PARP also abrogating the hyper-activation of
ERK1/2, the accumulation of autophagy-related proteins
like Beclin-1 (BECN1), Rab7 or its effector RILP elicited
by single β-catenin knockdown. These molecular changes
may relatively explain why a double β-catenin/NHERF1-
inhibitory strategy may be a fruitful mechanism-based
strategy to augment apoptotic death of CRC cells refractory
to Wnt/β-catenin-targeted therapeutics [3, 5, 6].
However, as physiological or pathological roles of
NHERF1 strictly depend on its subcellular localization,
targeted approaches aiming at modulating NHERF1 activ-
ity, rather than its overall expression, would be preferred to
preserve the normal functions of this versatile protein. By
far, particular attention has been paid to the NHERF1/
PDZ1-domain that governs its membrane recruitment/dis-
placement through a transient phosphorylation switch [7,
21–23]. By using a rational virtual screening, we herein
validated RS5517 as a novel NHERF1/PDZ1 ligand that
abrogates its nuclear entry exhibiting a remarkable cyto-
toxicity on β-catenin-depleted CRC cells which highly re-
express NHERF1.
Fig. 8 RS5517 prevents nuclear
import of NHERF1 and shβ-
catenin-mediated accumulation
of phospho-ERK1/2 and RILP
in CRC cells. a DLD1shβ-Cat
cells treated with 10 μM RS5517
or DMSO in the absence or
concomitant presence of Dox
(−Dox/+Dox) for 5 days were
stained using an anti-NHERF1
rabbit polyclonal primary
antibody followed by an IgG-
FITC secondary antibody and
DAPI staining for each indicated
treatment. Each confocal image
is representative of three
independent
immunofluorescence
experiments (Magnification,
×60). b Ls174Tshβ-Cat cells
were treated with 10 μM
RS5517 or DMSO in the
absence or concomitant presence
of 2 μg/mL of Dox (−Dox/
+Dox) for 5 days and then
fractionated to obtain purified
extracts from either membrane,
cytosol, and nucleus of cells, as
described in Methods section.
Equal amounts of each cell
extract (100 μg) were separated
by SDS-PAGE and probed with
the indicated antibodies. c
Ls174Tshβ-Cat cells were
exposed to 10 μM RS5517 in the
absence or concomitant presence
of 2 μg/mL of Dox (−Dox/
+Dox) for 5 days and total
lysates were then analyzed by
western blotting with the
indicated antibodies
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Although, further studies will exploit the safety profile of
RS5517 in vivo, understanding that β-catenin signaling
negatively regulates NHERF1 in CRC tumorigenesis will
trigger the refinement of Wnt-targeted approaches to over-
come the therapeutic resistance occurring at early disease
stages.
Materials and methods
Cells cultures and reagents
Colorectal cancer (CRC) cell lines Ls174T and DLD-1 were
purchased from the American Type Culture Collection
(Manassas, VA, USA) and routinely assessed to check their
identity [45]. Cells were stably transfected with Doxycy-
cline hyclate (Dox)-inducible short hairpin RNA (shRNA)
for β-catenin (Ls174Tshβ-Cat and DLD1shβ-Cat) or a
scramble control shRNA (shCtr), as previously described
[3, 45]. To obtain NHERF1 downregulation, Ls174Tshβ-
Cat and DLD1shβ-Cat were transfected with 250 nM of
NHERF1 shRNA (shNHERF1) or a scramble control
shRNA (shCtr) (sc-156113) (Santa Cruz Biotechnology,
CA, USA), according to the manufacturer’s instructions.
FH535 (Calbiochem, San Diego, CA) and pyrvinium
pamoate (Sigma-Aldrich) were resuspended in dimethyl-
sulfoxide (DMSO, Sigma-Aldrich).
RT-PCR
Total RNA of Ls174Tshβ-Cat and DLD1shβ-Cat cells was
isolated using Trizol reagent (Invitrogen, Carlsbad, CA).
The Nherf1 mRNA levels were determined using an RT-
PCR kit (New England Biolabs, Beverly, MA) and the
following primers: forward 5′-CCCAGTGGC-
TATGGCTTCAA-3′ and reverse 5′-GAAGTCTAG-
GATGGGGTCGG-3′. The primers for β-actin were:
forward 5′-CCACGGCTGCTTCCAGCTCC-3′ and reverse
5′-GGAGGGCCGACTCGTCAT-3′. The relative Nherf1
mRNA abundance versus β-actin mRNA was quantified by
Image J analysis.
Chromatin immunoprecipitation (ChIP) assay
A CHIP-KIP, including an anti-TCF4 antibody, a mouse
IgG control and Gapdh promoter primers was from Milli-
pore (#17-10109). An anti-TCF1 antibody (clone 7H3) was
also from Millipore. TCF-associated DNA immunopreci-
pitates were verified by qPCR using SYBR Green
Mix (TaKaRa) and Nherf1 promoter primers as
follows: Nherf1 5′-CCTCCGTCTTAATTCTCGAG-3′
(forward) and 5′-CCTTCACCTTCACAAACAAT-3′
(reverse). Data are reported as percent input of each IP
sample relative to input chromatin for each amplicon and
ChIP sample.
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Fig. 9 RS5517 induces CRC cell death when combined to pharma-
cological inhibitors of β-catenin. a Ls174Tshβ-Cat cells were treated
with 10 μM RS5517 as single agent or in combination with FH535 (1
μM) or pyrvinium pamoate (150 nM) for 4 days and a representative
image of one of the six fields captured from each well by using a
camera attached to an inverted Olympus IX51 microscope is shown. b
Ls174Tshβ-Cat or DLD1shβ-Cat cells treated with 10 μM RS5517
alone or in combination with FH535 (1 μM) or Pyrvinium pamoate
(150 nM) for 4 days were then labelled by Annexin V/propidium
iodide staining for apoptosis evaluation by flow cytometry. Values
represent the mean ± SD of three independent experiments (*P <
0.003). c Total lysates from Ls174Tshβ-Cat or DLD1shβ-Cat cells
treated with 10 μM RS5517 alone or in combination with FH535 (1
μM) or Pyrvinium pamoate (150 nM) for 4 days were analyzed by
western blotting with the indicated antibodies
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Immunofluorescence staining
Cells were assayed using an anti-NHERF1 (1:500; Ther-
moFisher, Rockford, IL) or β-catenin primary antibody
(1:500; BD Transduction Laboratories, Lexington, KY)
followed by Alexa Fluor 488-conjugated goat anti-rabbit
IgG-FITC or a goat anti-rabbit IgG-TRITC (1:1000;
Molecular Probes, Inc., Eugene, OR) secondary antibodies,
and then analyzed using a confocal laser scanning micro-
scope (LSM 710, Zeiss, Germany), equipped with a 60 oil-
immersion objective and a spatial resolution of 200 nm in
x–y and 100 nm in z.
Staining of monodansylcadaverine (MDC)-labeled
vacuoles
Cells were stained with 0.05 mM MDC in PBS at 37 °C for
10 min, washed and assayed by fluorescence microscope
(Nikon Eclipse TE300, Japan). Images were captured using
Image Pro-plus software.
Cell proliferation and apoptosis assays
Cells (105–505 cells/well) were treated with serial dilutions
of RS5517 or DMSO in the absence (−Dox) or presence
(+Dox) of Dox in a volume of 200 μl. Cell growth was
quantified by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl Tetrazolium bromide) (Sigma-Aldrich) according
to manufacturer’s recommendations. For apoptosis assays,
the cells were stained with Annexin V-PE (BD-PharMin-
gen, San Diego, CA) or Caspase-Glo assay kit (Promega)
and analyzed by flow cytometry.
Luciferase reporter assays, flow cytometry, and soft
agar clonogenic analysis
Cells were analyzed as previously described [45].
Subcellular fractionation assays
Cells were collected in the subcellular fractionation buffer
(SF buffer): 250 mM sucrose, 20 mM HEPES (pH 7.4),
10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA and EGTA, to
which 1 mM DTT and protease/phosphatase inhibitors
(1 mM PMSF; 5 mM NaF and 1 mM Na3VO4) were added
at time of use. Lysates were then put on a tube roller
(30–50 r.p.m.) at 4 °C for 30 min and centrifuged at 720×g
at 4 °C for 5 min. Pellet was washed with 500 μl of SF
buffer, centrifuged at 720×g at 4 °C for 10 min, and dis-
solved for 15 min in nuclear lysis buffer (NL buffer):
50 mM Tris-HCl (pH 8), 150Mm NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS, to which 10% glycerol
and protease/phosphatase inhibitors were added at time of
use. To obtain cytosolic fraction, the supernatant was cen-
trifuged at 10,000×g at 4 °C for 10 min and ultracentrifuged
at 100,000×g at 4 °C for 1 h. To obtain the membrane
fraction, the ultracentrifuged pellet was washed with SF
buffer and ultracentrifuged at 100,000×g at 4 °C for 1 h.
Last pellet was dissolved in NL buffer and sonicated on ice.
Pulse-chase analysis, immunoprecipitation, and
western blotting
Cells were assayed as previously described [45]. Primary
antibodies were as follows: total β-catenin was from BD
Transduction Laboratories, total NHERF1 from Thermo-
Fisher, total c-Myc, cyclin D1, p27, Rab7, RILP, V1G1,
Cathepsin D, and α-Tubulin were from Santa Cruz Bio-
technology Inc. (Santa Cruz, CA), total and phosphorylated
pERK1/2 (pThr202/Tyr204) MAPK, total AKT, LC3,
Beclin-1 (BECN1), and PARP were from Millipore.
Sample preparation and mass spectrometry
evaluation
Quantity of 20 μg of whole-protein extracts prepared using
Illustra TriplePrep kit (GE Healthcare) were diluted 10-fold
in 8M urea in 0.1 M Tris-HCl, pH 8.5, filtered into the
Microcon Ultracel YM-30 devices (Millipore), and cen-
trifuged at 14,000×g for 15 min. Samples were then further
diluted in 8M urea, centrifuged again, reduced in 10 mM
DTT for 30 min, and then alkylated in 50 mM IAM for
20 min. After four washes (2 in 8M urea and 2 in 50 mM
NH4HCO3), trypsin solution was added in an enzyme-to-
protein ratio of 1:100 w/w, and samples were maintained at
37 °C for 16 h. Peptides were centrifuged and acidified by
trifluoroacetic acid, desalted-concentrated on C-18 ZipTip
(Millipore), dried under vacuum and then resuspended in
20 µl of ACN/H2O (FA 0.1%) (2:98, v/v). Separation was
obtained using an EASY-nLC 1000 UPLC (Thermo Sci-
entific) through 75 mm × 2 cm pre-column with nanoViper
fittings (Acclaim pepMap 100, C18, 2 µm, Thermo Scien-
tific) and 50 mm ID × 150 mm analytical column with
nanoViper fittings (Acclaim PepMap RSLC, C18, 2 µm,
Thermo Scientific). Elution was carried out over 120 min by
using a 2-h gradient of ACN. The Q-Exactive instrument
(Thermo Scientific) was set up to a spray voltage of 1.6 kV
and the survey scans were taken at 70,000 FWHM (at m/z
400) resolving power in positive ion mode with a scan
range from 300 to 1600 m/z.
Database searching and bioinformatics analysis
Q-Exactive spectra were processed using the MaxQuant
proteomics software (version 1.5.3.8) and matched using
the Andromeda algorithm [46]. Trypsin was used as enzyme
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with two missed cleavages allowed. N-terminal acetylation
and methionine oxidation were variable modifications,
while carbamidomethylation of cysteines was a fixed
modification. An initial mass spectra accuracy of 6 p.p.m.
was selected, and the MS/MS tolerance was 20 p.p.m. for
the HCD data with a false discovery rate of 1% for peptides
and proteins identification. The MaxLFQ algorithm was
used for assessing relative, label-free quantification of the
proteins [47].
Chemical synthesis of the RS5517 derivative
RS5517, namely 3-benzyl-5-chloro-N-(4-(hydroxymethyl)
phenyl)-1H-indole-2-carboxamide, was synthesized by
coupling reaction of 3-benzyl-5-chloro-1H-indole-2-car-
boxylic acid with protected (4-(hydroxymethyl)aniline in
the presence of PyBOP reagent and triethylamine in DMF.
The product was deprotected by reaction with tetra-
butylammonium fluoride solution (1M in anhydrous THF).
Virtual screening studies
The NHERF1 PDZ1 domain was retrieved from the Protein
Data Bank, under the PDB accession code 21GQ4 and the
substrates (DSLL and ETVM) were drawn by Maestro
(Schrödinger Release 2016-4: Maestro, Schrödinger, LLC,
New York, NY, 2016) and analysed by molecular dynamics
with Amber 12 [48]. The minimized structure was solvated
in a periodic octahedron simulation box using TIP3P water
molecules, providing a minimum of 10 Å of water between
the protein surface and any periodic box edge. Following
minimization, the entire system was heated to 298 K
(20 ps), and the simulation was conducted at 298 K with
constant pressure, periodic boundary condition and shake
bond length condition (ntc= 2). Trajectories analysis
were carried out by the cpptraj modules [25]. This led
to 5 structures for each complex which were used to
draw a consensus pharmacophore model by Phase [26]. An
in-house library of about 6000 compounds were docked
into the binding site of each structures by Plants [49].
Structures fitting the pharmacophore queries were
selected for biological evaluation. Picture was depicted by
Pymol (PyMOL version 1.2r1. DeLanoScientificLLC:San-
Carlos, CA).
In vitro binding studies
A NHERF1 PDZ1 subcloned in pETG41 plasmid was
kindly obtained from Dr. Nicolas Wolff (Pasteur Institute,
Paris, France). A site-directed mutagenesis by Quickchange
Lighting mutagenesis kit was confirmed by DNA sequen-
cing. A dansylated peptide relative to the C-terminal portion
of the β2-adrenergic receptor, D-NDSLL, was from JPT
Peptide Technologies (Berlin, Germany) and purified using
HPLC. Equilibrium binding experiments were carried out in
the presence of 50 mM Na phosphate buffer, pH 7.2,
300 mM NaCl at 25 °C by monitoring fluorescence upon
exciting the sample at 280 nm and measuring emission on a
Fluoromax single-photon spectrofluorometer (Jobin-Yvon,
NJ, USA) [50].
Statistical analysis
Data are reported as the mean ± SEM. Significance levels
were determined with the Student's t-test. Proteomic sta-
tistical analysis was perfomed with the Perseus software
(version 1.5.2.4). Multiple-samples tests were performed
using ANOVA test by using a false discovery rate threshold
of 0.05 and preserving grouping in randomization. Hier-
archical clustering of proteins was performed in Perseus on
logarithmized intensities after z-score normalization of
the data, using Euclidean distances. Gene Ontology (GO)
and Kyoto Encyclopedia of Genes and Genomes
(KEGG) analysis of our protein dataset was performed by
STRING version 10 (http://string-db.org) (Nucleic Acids
Res 2015; 43(Database issue):D447-52. doi: 10.1093/nar/
gku1003).
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